

## Hematologia

	2008	2009
<b>Personal assignat al servei</b>		
Facultatius	5	5
Residents	3	3
<b>Activitat d'hospitalització</b>		
Altes externes	296	267
Estades	3.907	3.092
Estada mitjana (pacients ingressats)	13,2	11,6
Pressió d'urgències(%)	45,1	38,95
Interconsultes	275	450
<b>Activitat ambulàtoria</b>		
Primeres visites	1.502	1.517
Visites successives	30.476	28.110
Total visites	31.978	29.627
Índex de successives / primeres	20,29	18,53
<b>Hospital de dia</b>		
Nombre de sessions	2.550	2.846
<b>Proves complementàries</b>		
Biòpsies	96	70
<b>Indicadors de 'Case-Mix' (1)</b>		
Raó de funcionament estàndard		0,84
Pes mitjà	2,7961	2,8014

(1) Veure glossari a la pàgina \_\_

**Servei d'Hematologia**  
**Publicacions 2009**

**Articles originals**

Abella E, Gimenez T, Gimeno J, Cervera M, Pedro C, Gimeno E, Alvarez A, Salar A, Bellosillo B, Serrano S, Besses C. **Diarrheic syndrome as a clinical sign of intestinal infiltration in progressive B-cell chronic lymphocytic leukemia.** Leuk Res 2009; 33(1): 159-161. **IF:** 2.39. **Q:** 3 (HEMATOLOGY ).

Álvarez-Larran A, Bellosillo B, Martínez-Avilés L, Saumell S, Salar A, Abella E, Gimeno E, Serrano S, Florensa L, Sánchez-González B, Pedro C, Besses C. **Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients.** Br J Haematol 2009; 146(5): 504-509. **IF:** 4.478. **Q:** 1 (HEMATOLOGY ).

Álvarez-Larran A, del Río-Garma J, Pujol M, de la Rubia J, Hernández-Jodra M, Borrell M, González-Porras JR, García-Gala JM, Viejo A, Enríquez L, Arbona C, García-Erce JA, Noblejas AG, Pereira A. **Newly diagnosed versus relapsed idiopathic thrombotic thrombocytopenic purpura: a comparison of presenting clinical characteristics and response to treatment.** Ann Hematol 2009; 88(10): 973-978. **IF:** 2.454. **Q:** 2 (HEMATOLOGY ).

Arellano-Rodrigo E, Álvarez-Larran A, Reverter JC, Colomer D, Villamor N, Bellosillo B, Cervantes F. **Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: Relationship with thrombosis occurrence and JAK2 V617F allele burden.** Am J Hematol 2009; 84(2): 102-108. **IF:** 2.126. **Q:** 3 (HEMATOLOGY ).

Baró C, Espinet B, Salido M, Colomo L, Luño E, Florensa L, Ferrer A, Salar A, Campo E, Serrano S, Solé F. **FOXP1 status in splenic marginal zone lymphoma: a fluorescence in situ hybridization and immunohistochemistry approach.** Histol Histopathol 2009; 24(11): 1399-1404. **IF:** 2.194. **Q:** 2 (PATHOLOGY ).

Bosch F, Abrisqueta P, Villamor N, Terol MJ, González-Barca E, Ferra C, González-Díaz M, Abella E, Delgado J, Carbonell F, García-Marco JA, Escoda L, Ferrer S, Monzó E, González Y, Estany C, Jarque I, Salamero O, Muntañola A, Montserrat E. **Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone a New, Highly Active Chemoimmunootherapy Regimen for Chronic Lymphocytic Leukemia.** J Clin Oncol 2009; 27(27): 4578-4584. **IF:** 17.157. **Q:** 1 (ONCOLOGY ).

Gallardo F, García-Muret P, Servitje O, Estrach T, Bielsa I, Salar A, Abella E, Barranco C, Pujol RM. **Cutaneous lymphomas showing prominent granulomatous component: clinicopathological features in a series of 16 cases.** J Eur Acad Dermatol Venereol 2009; 23(6): 639-647. **IF:** 2.276. **Q:** 2 (Dermatology).

Gallardo F, Pujol RM, Barranco C, Salar A. **Progressive Painless Swelling of Glans Penis: Uncommon Clinical Manifestation of Systemic Non-Hodgkin's Lymphoma.** Urology 2009; 73(4): 929.e3-929.e5. **IF:** 2.242. **Q:** 2 (UROLOGY & NEPHROLOGY ).

García-Marco J, Panizo C, Sánchez E, Debén G, Álvarez-Larran A, González-Barca E, Sancho JM, Peñarrubia MJ, García-Cerecedo T, García-Vela JA. **Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma.** Cancer 2009; 115(9): 1892-1898. **IF:** 5.238. **Q:** 1 (ONCOLOGY ).

Giralt M, Navas V, Hernández-Nieto L, Burgaleta C, Carbonell F, Ramírez G, Vicente V, Besses C, y en representación del Grupo de Estudio de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). **Análisis retrospectivo de la eficacia y la tolerabilidad de anagrelida en pacientes con trombocitemia esencial: registro español de trombocitemia esencial.** Med Clin (Barc) 2009; 133(3): 86-90. **IF:** 1.258. **Q:** 3 (MEDICINE, GENERAL & INTERNAL ).

Martínez-López J, Rivero A, Rapado I, Montalbán C, Paz-Carreira J, Canales MA, Martínez R, Sánchez-Godoy P, Fernández-Sevilla A, Peñalver FJ, González M, Prieto E, Salar A, Burgaleta C, Queizan JA, Peñarrubia MJ, Monteagudo MD, Cabrera C, De la Serna J, Tomás JF. **Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide.** Leukemia Lymphoma 2009; 50(8): 1283-1289. **IF:** 1.939. **Q:** 3 (HEMATOLOGY ).

Pérez-García A, Brunet S, Berlanga JJ, Tormo M, Nomdedeu JF, Guàrdia R, Ribera JM, Heras I, Llorente A, Hoyos M, Esteve J, Besalduch J, Bueno J, Sierra J, Gallardo D, Grupo cooperativo para el estudio y tratamiento de las leucemias agudas y mielodisplasias' (CETLAM) (...Pedro C, Florensa L,...). **CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy.** Leukemia 2009; 23(3): 486-491. **IF:** 8.634. **Q:** 1 (HEMATOLOGY ).

Quijano S, López A, Sancho JM, Panizo C, Debén G, Castilla C, García-Vela JA, Salar A, Alonso-Vence N, González-Barca E, Peñalver FJ, Plaza-Villa J, Morado M, García-Marco J, Arias J, Briones J, Ferrer S, Capote J, Nicolás C, Orfao A. **Identification of Leptomeningeal Disease in Aggressive B-Cell Non-Hodgkin's Lymphoma: Improved Sensitivity of Flow Cytometry.** J Clin Oncol 2009; 27(9): 1462-1469. **IF:** 17.157. **Q:** 1 (ONCOLOGY ).

Salar A, Domingo-Doménech E, Estany C, Canales MA, Gallardo F, Servitje O, Fraile G, Montalbán C. **Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.** Cancer 2009; 115(22): 5210-5217. **IF:** 5.238. **Q:** 1 (ONCOLOGY ).

## **Notes**

Fernández-Casado A, Sánchez-González B. **Images in clinical medicine. Tongue necrosis in a patient with essential thrombocytosis.** New Engl J Med 2009; 360(22): e28. **IF:** 50.017. **Q:** 1 (MEDICINE, GENERAL & INTERNAL ).

Gimeno E, Giménez MT, Álvarez-Larran A, Gallardo F, Ferrer A, Bellosillo B, Besses C, Salar A. **Central nervous system involvement from primary cutaneous large B-cell lymphoma of the leg.** Leuk Res 2009; 33(7): e59-e60. **IF:** 2.39. **Q:** 3 (HEMATOLOGY ).

Moreno MJ, Lozano ML, Ferrer F, Bellosillo B, Besses C, Vicente V, Martínez C. **ABO blood group does not increase the risk of thrombosis in Philadelphia-negative myeloproliferative disorders.** Blood Coagul Fibrin 2009; 20(5): 390-392. **IF:** 1.398. **Q:** 4 (HEMATOLOGY ).

Sánchez-González B, García-García M, Serrano S, Besses C, Salar A. **Bendamustine-containing immunochemotherapy is active in transformed follicular lymphoma with overexpression of p53.** Leukemia Lymphoma 2009; 50(3): 455-456. **IF:** 1.939. **Q:** 3 (HEMATOLOGY ).

## **Revisions**

Cervantes F, Arellano-Rodrigo E, Álvarez-Larran A. **Blood cell activation in myeloproliferative neoplasms.** Haematologica 2009; 94(11): 1484-1488. **IF:** 5.978. **Q:** 1 (HEMATOLOGY ).